Leftagraph

Every financial statement,
one clean chart.

Search any US-listed company. Data straight from SEC filings.

PROBuild your own list with the screener

Exelixis Inc (EXEL) financial statements

Number look wrong? Tell us

Data table
PROBuild your own list with the screener

Exelixis Inc (EXEL), most recent 12 months reported: revenue $2.44B, net income $860.62M, free cash flow $1.17B. Latest balance sheet on file: liquid cash $839.38M. From SEC filings. Others in Biological Products, (No Diagnostic Substances): Amgen Inc. · GILEAD SCIENCES, INC. · BIOGEN INC. · NEUROCRINE BIOSCIENCES INC · Moderna, Inc. · QIAGEN N.V. · HALOZYME THERAPEUTICS, INC. · BIO-TECHNE Corp

Stock screener

Watchlist